MS Briefs

High-dose biotin treatment tied to increased risk of relapse in progressive MS


Key clinical point: The follow-up of patients with progressive multiple sclerosis (PMS) starting high-dose biotin (HDB) should include careful assessment of clinical and radiological activity to monitor the potential pro-inflammatory effect of biotin.

Major finding: In the crossover analysis among patients who received HDB (n=42), the number of relapses was statistically and clinically significantly higher after vs. before biotin initiation (incident rate ratio, 7.4; P less than .0001). With the propensity score matching method, relapse risk was significantly higher in the biotin vs. control group (hazard ratio [HR], 4.3; P = .01). The inverse probability of treatment weighting method with 440 control participants showed consistent results with higher risk in the biotin group (HR, 5.1; P less than .0001).

Study details: This study evaluated the association between exposure to HDB and the risk of relapse among 482 patients with PMS.

Disclosures: No study sponsor was identified. The authors declared no conflicts of interest.

Citation: Branger P et al. Neurotherapeutics. 2020 Jun 15. doi: 10.1007/s13311-020-00880-z .

Next Article: